Extracorporeal Membrane Oxygenation (ECMO): Blood Cells

Stopped early

Conditions studied: Extracorporeal Membrane Oxygenation

In brief

The objective of the study is to predict outcomes of patients on extracorporeal membrane oxygenation (ECMO) therapy by correlating cytokines and inflammatory cell patterns to clinical outcomes using data collected in the ECMO Registry at Spectrum Health.

Key facts

Study ID

NCT02748668

Run by

Corewell Health West

People needed

371

Starts

2015-01-20

Expected to finish

2023-08-23

Last updated by the study team

2024-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Greater than or equal to 18 years of age
• Subject presents to the CTICU at Butterworth Campus, Spectrum Health and is critically ill in the ICU needing ECMO therapy.

You may not qualify if…

• Subject is less than 18 years of age
• Known prisoner
• Control Subjects:
• Inclusion Criteria
• Greater than 18 years of age
• Without any known cardiovascular, lung, or autoimmune disease.
• Exclusion Criteria:
• Less than or equal to 18 years of age
• Known cardiovascular, lung, or autoimmune disease

Where it is running

• Spectrum Health — Grand Rapids, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.